Karius Karius Receives NY State Approval for Infectious Disease Liquid Biopsy Test The permit covers the test for all five pathogen categories: bacteriology, mycobacteriology, mycology, parasitology, and virology. Karius Cell-Free DNA Method to Detect Infection Validated in Study Premium The liquid biopsy test compares fragments of cfDNA to a reference database of more than 1,400 microbial pathogens to determine infection. Karius to Widen Adoption, Improve Infectious Dx Technology With $165M Series B Funding Premium The firm argues that its tests allows hospitals to expedite patient treatment, while curbing the costs of one-off tests and medication, and minimizing the length of a patient's stay. Karius Raises $165M in Series B Financing Round The firm will use the funding to expand access to its microbial cell-free DNA technology to help doctors diagnose infectious disease. Blood-Based Sequencing Test Identifies Pediatric Cancer Infections Before Symptoms St. Jude Children's Research Hospital researchers evaluated a microbial cell-free DNA sequencing test from infectious disease diagnostics firm Karius. Feb 14, 2019 Karius Infectious Disease Dx Shows Promise, but Questions Remain on Clinical Indication Premium Nov 29, 2018 Karius Secures $25M Loan Oct 26, 2018 Karius Inks Deal to Launch Infectious Disease Test in Brazil Oct 8, 2018 Karius Collaborators Report Interim Study Results at IDWeek Premium May 11, 2018 New Products Posted to GenomeWeb: Bio-Rad, Karius, Intermountain Healthcare, More Breaking News FDA Revises SARS-CoV-2 Test Emergency Use Authorization Requirements to Account for Variants Geisinger Wins $5M NIH Grant to Develop Point-of-Care Genetic Diagnostic Tool Second Genome, Virginia Commonwealth University Partner on NASH Biomarker Discovery LGC Receives CE Mark for AccuPlex SARS-CoV-2, Flu A/B, RSV Reference Material Kit Esophageal Cancer Testing Firm Lucid Diagnostics Files For IPO Twist Bioscience, DeepCDR Collaborate on Antibody Library Design The Scan Booster for At-Risk The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk. Preprints OK to Mention Again Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications. Hundreds of Millions More to Share The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post. Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.